Director at Cosmos Health (NASDAQ: COSM) awarded 40,000 shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Cosmos Health Inc. director Aslidis Anastasios received an award of 40,000 shares of Common Stock on May 19, 2026, granted under the company’s 2024 & 2025 Omnibus Incentive Plan as equity compensation exempt under Rule 16b-3.

The award reflects the vesting and conversion of an equal number of Restricted Stock Units into common shares at a stated value of $0.283 per share. After these transactions, Anastasios directly holds 100,000 shares of Common Stock. The filing shows no open‑market purchases or sales, only compensation-related acquisitions.

Insider Trade Summary

40,000 shares exercised/converted

Mixed 2 txns

Insider Aslidis Anastasios

Role null

Type	Security	Shares	Price	Value
Conversion	Restricted Stock Unit	40,000	$0.00	--
Grant/Award	Common Stock, par value $.001	40,000	$0.283	$11K

Holdings After Transaction: Restricted Stock Unit — 0 shares (Direct, null); Common Stock, par value $.001 — 100,000 shares (Direct, null)

Footnotes (1)

Reflects the award of 40,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

Key Figures

Equity award: 40,000 shares Award value per share: $0.283 per share RSUs converted: 40,000 units +4 more

7 metrics

Equity award 40,000 shares Common Stock granted May 19, 2026

Award value per share $0.283 per share Common Stock, par value $0.001

RSUs converted 40,000 units Restricted Stock Units converted into Common Stock

Post-transaction holdings 100,000 shares Common Stock held directly after award

Exercise price of RSUs $0.0000 Conversion of Restricted Stock Units into Common Stock

RSU exercise date May 19, 2026 Grant and vesting date under Omnibus Incentive Plan

RSU expiration date May 19, 2036 Expiration date referenced for RSU award

Key Terms

Restricted Stock Unit, Omnibus Incentive Plan, Rule 16b-3

3 terms

Restricted Stock Unit financial

"The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Omnibus Incentive Plan financial

"pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3"

An omnibus incentive plan is a single, flexible program a company uses to give employees and executives different types of pay tied to performance — for example stock options, restricted shares, cash bonuses and other awards — all governed by one set of rules. It matters to investors because it determines how many new shares may be created, how leaders are motivated and how much the company will spend on compensation over time; think of it as a master toolbox that affects both costs and the total share supply.

Rule 16b-3 regulatory

"in a transaction exempt under Rule 16b-3"

Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/11/2026 - 05:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslidis Anastasios

(Last)

(First)

(Middle)

5 AG. GEORGIOU STR.

(Street)

PILEA

THESSALONIKI

TK57001

(City)

(State)

(Zip)

GREECE

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cosmos Health Inc. [ COSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $.001	05/19/2026	05/19/2026	A⁽¹⁾		40,000	A	$0.283	100,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Unit	⁽²⁾	05/19/2026	05/19/2026	C			40,000	05/19/2026	05/19/2036	Common Stock, par value $.001	40,000	$0	0	D

Explanation of Responses:

1. Reflects the award of 40,000 shares of Common Stock granted on May 19, 2026, pursuant to the Issuer's 2024 & 2025 Omnibus Incentive Plan, in a transaction exempt under Rule 16b-3.

2. The RSUs were granted on May 19, 2026, under the Issuer's 2024 & 2025 Omnibus Incentive Plan and vested on the date of the grant, in a transaction exempt under Rule 16b-3.

	/s/ Anastasios Aslidis	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Cosmos Health (COSM) director Aslidis Anastasios report in this Form 4?

The Form 4 shows director Aslidis Anastasios acquiring 40,000 Cosmos Health common shares via an equity award. These shares came from vested RSUs granted under the 2024 & 2025 Omnibus Incentive Plan and were recorded as compensation, not open-market trading.

How many Cosmos Health (COSM) shares did the director receive and at what value?

Anastasios received 40,000 Cosmos Health common shares, recorded at $0.283 per share. The shares were issued through the vesting and conversion of Restricted Stock Units granted under the company’s 2024 & 2025 Omnibus Incentive Plan as director compensation.

What is Aslidis Anastasios’s Cosmos Health (COSM) ownership after the reported transactions?

Following the reported award and RSU conversion, Anastasios directly owns 100,000 shares of Cosmos Health common stock. This figure reflects the updated position after 40,000 RSUs granted under the 2024 & 2025 Omnibus Incentive Plan vested into common shares.

Were the Cosmos Health (COSM) transactions open-market buys or sells?

The transactions were not open-market buys or sells. They reflect an equity award and the conversion of 40,000 Restricted Stock Units into common shares, treated as compensation and reported as transactions exempt from Section 16(b) under Rule 16b-3.

What role did Restricted Stock Units play in this Cosmos Health (COSM) Form 4?

The filing shows 40,000 Restricted Stock Units granted under the 2024 & 2025 Omnibus Incentive Plan that vested on May 19, 2026. These RSUs were converted into an equal number of Cosmos Health common shares in a transaction exempt under Rule 16b-3.

Under which plan were the Cosmos Health (COSM) shares and RSUs granted to the director?

Both the 40,000 common shares and the 40,000 Restricted Stock Units were granted under Cosmos Health’s 2024 & 2025 Omnibus Incentive Plan. The awards vested on May 19, 2026 and are reported as Rule 16b-3 exempt director compensation.